Our ADCC-enhanced antibody platform is mainly based on gene editing technology to knock-out the FUT8 protein in CHO-K1 host cells for producing antibodies, and the antibodies produced by the engineered host cells are completely free fucose. Since the fucose in the Fc region of the antibody hinders the binding of the antibody to FcγRIIIa (CD16a), the afucosylated Fc region increases the affinity of the antibody to FcγRIIIa, so the afucosylated antibody can recruit more effector cells to be to the tumor site to enhance the effect of ADCC (one of the main mechanisms of therapeutic antibodies in cancer treatment). We have currently developed six ADCC-enhanced antibody drug candidates, all of which are in clinical development stage.